

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Use of at least one kinase inhibitor for making drugs for inducing differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti for treating deafness.
2. (Original) The use of claim 1, wherein said kinase inhibitor is selected in the group comprising purine derivatives.
2. (Cancelled)
3. (Original) The use of claim 2, wherein said purine derivatives are selected in the group comprising roscovitine, indirubins and purvulanols.
4. (Currently Amended) The use of ~~any one of claims 1 to 3~~ claim 1, wherein said kinase inhibitors are administered parenterally, rectally, topically, transdermally or orally.
5. (Original) The use of claim 4, wherein said kinase inhibitors are administered by the oral or injectable route.
6. (Original) The use of claim 5, wherein said kinase inhibitors are under the form of lozenges, compressed tablets, pills, tablets, capsules, drops, syrups, suspensions or emulsions.
7. (Currently Amended) The use of ~~any one of claims 4 to 6~~ claim 4, wherein the pharmaceutical compositions comprise 100 to 1000 mg of active principle per dose unit, preferably 300 to 600 mg.
8. (Original) The use of claim 5, wherein said kinase inhibitors are administered under the form of injectable solutions for the intravenous, subcutaneous or intramuscular route, formulated from sterile or sterilizable solutions, or under the form of suspensions or emulsions.

9. (Original) The use of claim 8, wherein said injectable forms comprise 100 to 1000 mg of said compound, or a pharmaceutically acceptable salt thereof, preferably 300 to 600 mg, per dose unit

10. (New) The use of claim 2, wherein said kinase inhibitor is selected in the group comprising purine derivatives.